With $200M in new cash, Synthego wants to become the manufacturing bedrock for CRISPR. But where are its customers?

Jason Mast

Editor

After nearly a decade developing CRISPR-based tools to help researchers in academia and biotech run their experiments, Synthego is getting into a new game: manufacturing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

With $200M in new cash, Synthego wants to become the manufacturing bedrock for CRISPR. But where are its customers?

Jason Mast

Editor

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

Exclusive: Influential Democrat will oppose Biosecure Act ahead of House vote

Astellas CEO talks future beyond Xtandi as Japanese drugmaker puts roots in Boston

BridgeBio sticks to script for ATTR-CM as Alnylam cleans up ‘typo’ snafu

Roche's Spark loses CEO to RNA upstart; Ex-Elevation Oncology chief takes over at Affimed

Lilly inks obesity deal with seed-stage RNA startup as its genetic medicines effort enters the spotlight

How to secure full enrollment and a 30x ROI: A conversation with the CEO of the boutique enrollment agency doing just ...

With $200M in new cash, Syn­thego wants to be­come the man­u­fac­tur­ing bedrock for CRISPR. But where are its cus­tomers?

Editor

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

With $200M in new cash, Synthego wants to become the manufacturing bedrock for CRISPR. But where are its customers?